Correspondence 0001477932-24-001883 from Nascent Biotech Inc. (NBIO) (CIK 0001622057)
Nascent Biotech Inc. (NBIO) (CIK 0001622057)
Date: April 5, 2024 · CIK: 0001622057 · Accession: 0001477932-24-001883
AI Filing Summary & Sentiment
File numbers found in text: 333-277960
Letter
nbio_corresp.htmNASCENT BIOTECH INC.
623 17th Street Suite 4
Vero Beach, FL 32960
April 4, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tyler Howes, Esq.
RE:
Acceleration Request for Nascent Biotech Inc.
Registration Statement on Form S-1 (File No. 333-277960)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nascent Biotech Inc. (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement be accelerated so that it may come effective at 12:00 p.m., Washington D.C. time, on Monday, April 8, 2024, or as soon as practicable thereafter. In this regard, the Company is aware of its obligations under the Securities Act.
The Company acknowledges that:
·
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
·
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
·
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
NASCENT BIOTECH INC.
Show Raw Text
CORRESP
1
filename1.htm
nbio_corresp.htmNASCENT BIOTECH INC.
623 17th Street Suite 4
Vero Beach, FL 32960
April 4, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tyler Howes, Esq.
RE:
Acceleration Request for Nascent Biotech Inc.
Registration Statement on Form S-1 (File No. 333-277960)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nascent Biotech Inc. (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement be accelerated so that it may come effective at 12:00 p.m., Washington D.C. time, on Monday, April 8, 2024, or as soon as practicable thereafter. In this regard, the Company is aware of its obligations under the Securities Act.
The Company acknowledges that:
·
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
·
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
·
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
NASCENT BIOTECH INC.
Lowell Holden, CFO